Australia - inglese - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - alogliptin benzoate,pioglitazone hydrochloride -

Australia - inglese - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - alogliptin benzoate,pioglitazone hydrochloride -

Australia - inglese - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - alogliptin benzoate, quantity: 34 mg (equivalent: alogliptin, qty 25 mg); pioglitazone hydrochloride, quantity: 16.53 mg (equivalent: pioglitazone, qty 15 mg) - tablet, film coated - excipient ingredients: iron oxide yellow; purified talc; titanium dioxide; croscarmellose sodium; hypromellose; lactose monohydrate; magnesium stearate; hyprolose; mannitol; macrogol 8000; microcrystalline cellulose; shellac; ethanol absolute; iron oxide black; 1-butanol - oseni is indicated to improve glycaemic control in adult patients (> or = 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control and treatment with both alogliptin and pioglitazone is appropriate,- when treatment with metformin or pioglitazone alone does not provide adequate control; or,- in combination with metformin when dual therapy does not provide adequate control.,oseni can also be used to replace separate tablets of alogliptin and pioglitazone in patients already being treated with this combination.

Uganda - inglese - National Drug Authority

takeda pharmaceuticals u.s.a inc - alogliptin benzoate + metformin hydrochloride - oral solid ordinary film-coated tablets - 12.5mg + 1000mg

Giappone - inglese - すりの適正使用協議会 RAD-AR Council, Japan

teijin pharma limited - alogliptin benzoate; metformin hydrochloride - faint red oval tablets, major axis: 13.7 mm, minor axis: 8.7 mm, thickness: approx. 6.6 mm

Australia - inglese - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - pioglitazone hydrochloride, quantity: 33.06 mg (equivalent: pioglitazone, qty 30 mg); alogliptin benzoate, quantity: 34 mg (equivalent: alogliptin, qty 25 mg) - tablet, film coated - excipient ingredients: iron oxide yellow; magnesium stearate; hyprolose; microcrystalline cellulose; lactose monohydrate; purified talc; titanium dioxide; hypromellose; croscarmellose sodium; iron oxide red; macrogol 8000; mannitol; shellac; ethanol absolute; iron oxide black; 1-butanol - oseni is indicated to improve glycaemic control in adult patients (> or = 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control and treatment with both alogliptin and pioglitazone is appropriate,- when treatment with metformin or pioglitazone alone does not provide adequate control; or,- in combination with metformin when dual therapy does not provide adequate control.,oseni can also be used to replace separate tablets of alogliptin and pioglitazone in patients already being treated with this combination.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - pioglitazone hydrochloride, quantity: 49.59 mg (equivalent: pioglitazone, qty 45 mg); alogliptin benzoate, quantity: 34 mg (equivalent: alogliptin, qty 25 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; hyprolose; iron oxide red; lactose monohydrate; purified talc; mannitol; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; macrogol 8000; shellac; ethanol absolute; iron oxide black; 1-butanol - oseni is indicated to improve glycaemic control in adult patients (> or = 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control and treatment with both alogliptin and pioglitazone is appropriate,- when treatment with metformin or pioglitazone alone does not provide adequate control; or,- in combination with metformin when dual therapy does not provide adequate control.,oseni can also be used to replace separate tablets of alogliptin and pioglitazone in patients already being treated with this combination.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - pioglitazone hydrochloride, quantity: 16.53 mg (equivalent: pioglitazone, qty 15 mg); alogliptin benzoate, quantity: 34 mg (equivalent: alogliptin, qty 25 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; purified talc; hypromellose; croscarmellose sodium; hyprolose; microcrystalline cellulose; titanium dioxide; magnesium stearate; mannitol; macrogol 8000; iron oxide yellow; shellac; ethanol absolute; iron oxide black; 1-butanol - oseni is indicated to improve glycaemic control in adult patients (> or = 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control and treatment with both alogliptin and pioglitazone is appropriate,- when treatment with metformin or pioglitazone alone does not provide adequate control; or,- in combination with metformin when dual therapy does not provide adequate control.,oseni can also be used to replace separate tablets of alogliptin and pioglitazone in patients already being treated with this combination.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - alogliptin benzoate, quantity: 34 mg - tablet, film coated - excipient ingredients: iron oxide red; microcrystalline cellulose; hyprolose; macrogol 8000; croscarmellose sodium; mannitol; titanium dioxide; hypromellose; magnesium stearate; shellac; ethanol absolute; iron oxide black; 1-butanol - vipidia is indicated to improve glycaemic control in adult patients (>= 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control, as add on to metformin, a sulphonylurea, a thiazolidinedione, insulin (with or without metformin), or in combination with metformin and a thiazolidinedione when dual therapy does not provide adequate glycaemic control.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - alogliptin benzoate, quantity: 8.5 mg - tablet, film coated - excipient ingredients: mannitol; hypromellose; macrogol 8000; hyprolose; microcrystalline cellulose; titanium dioxide; croscarmellose sodium; magnesium stearate; iron oxide red; shellac; ethanol absolute; iron oxide black; 1-butanol - vipidia is indicated to improve glycaemic control in adult patients (>= 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control, as add on to metformin, a sulphonylurea, a thiazolidinedione, insulin (with or without metformin), or in combination with metformin and a thiazolidinedione when dual therapy does not provide adequate glycaemic control.